Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · IEX Real-Time Price · USD
5.31
-0.08 (-1.48%)
Apr 26, 2024, 12:44 PM EDT - Market open
Travere Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for TVTX stock have an average target of 18, with a low estimate of 9.00 and a high estimate of 35. The average target predicts an increase of 238.98% from the current stock price of 5.31.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for TVTX stock from 14 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 4 | 4 |
| Buy | 6 | 6 | 6 | 6 | 5 | 5 |
| Hold | 5 | 4 | 4 | 4 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 15 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $17 → $19 | Strong Buy | Maintains | $17 → $19 | +257.82% | Apr 24, 2024 |
| Wedbush | Wedbush | Buy Reiterates $13 | Buy | Reiterates | $13 | +144.82% | Apr 17, 2024 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +220.15% | Mar 13, 2024 |
| Wells Fargo | Wells Fargo | Hold Maintains $8 → $9 | Hold | Maintains | $8 → $9 | +69.49% | Feb 16, 2024 |
Financial Forecast
Revenue This Year
220.43M
from 145.24M
Increased by 51.77%
Revenue Next Year
315.26M
from 220.43M
Increased by 43.02%
EPS This Year
-3.24
from -1.50
EPS Next Year
-1.78
from -3.24
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 280.4M | 539.0M | 681.1M | 1.0B | 1.3B |
| Avg | 220.4M | 315.3M | 446.7M | 581.4M | 742.9M |
| Low | 170.5M | 213.6M | 297.4M | 175.4M | 293.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 93.0% | 144.5% | 116.1% | 131.7% | 118.8% |
| Avg | 51.8% | 43.0% | 41.7% | 30.1% | 27.8% |
| Low | 17.4% | -3.1% | -5.7% | -60.7% | -49.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.55 | 0.17 | 1.10 | 1.88 | 2.36 |
| Avg | -3.24 | -1.78 | -0.09 | 0.75 | 1.23 |
| Low | -4.02 | -2.41 | -1.42 | 0.25 | 0.63 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 215.1% |
| Avg | - | - | - | - | 64.3% |
| Low | - | - | - | - | -16.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.